These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1541981)

  • 21. Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.
    Schomburg A; Kirchner H; Atzpodien J
    J Cancer Res Clin Oncol; 1993; 119(12):745-55. PubMed ID: 8408187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.
    Blancher A; Roubinet F; Grancher AS; Tremoulet M; Bonaté A; Delisle MB; Calot JP; Pourreau C; Franks C; Ducos J
    Eur Cytokine Netw; 1993; 4(5):331-41. PubMed ID: 8117934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
    Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
    Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
    Vlasveld LT; Rankin EM; Hekman A; Rodenhuis S; Beijnen JH; Hilton AM; Dubbelman AC; Vyth-Dreese FA; Melief CJ
    Br J Cancer; 1992 May; 65(5):744-50. PubMed ID: 1586602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
    Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
    Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
    Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
    Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group.
    Dillman RO; Wiemann M; Oldham RK; Soori G; Bury M; Hafer R; Church C; DePriest C
    Cancer Biother; 1995; 10(4):265-71. PubMed ID: 8590891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer.
    Taylor CW; Chase EM; Whitehead RP; Rinehart JJ; Neidhart JA; Gonzalez R; Bunn PA; Hersh EM
    J Immunother (1991); 1992 Apr; 11(3):176-83. PubMed ID: 1515422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
    Meffert M; Schomburg A; Hänninen EL; Menzel T; Vocke S; Dallmann I; Grosse J; Duensing S; Buer J; Kirchner H
    Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.
    Lillehei KO; Mitchell DH; Johnson SD; McCleary EL; Kruse CA
    Neurosurgery; 1991 Jan; 28(1):16-23. PubMed ID: 1994273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
    Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
    Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
    Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
    J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma.
    Coates A; Rallings M; Hersey P; Swanson C
    J Interferon Res; 1986 Feb; 6(1):1-4. PubMed ID: 2871116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.
    Atzpodien J; Körfer A; Palmer PA; Franks CR; Poliwoda H; Kirchner H
    Ann Oncol; 1990 Sep; 1(5):377-8. PubMed ID: 2261378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of intraperitoneal recombinant interleukin-2 and ex vivo activated intracavitary lymphocytes in patients with malignant peritoneal spread: I. Clinical aspects.
    Lurie H; Rakovsky E; Fenig E; Davidovitz J; Adler A
    Mol Biother; 1989; 1(3):163-9. PubMed ID: 2604915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combined immunotherapy using interferon-alpha, interleukin-2 and lymphokine-activated killer cells--improvement of quality of life in patients with advanced renal cell carcinoma].
    Watanabe J; Hattori T; Satoh M; Akimoto M
    Nihon Hinyokika Gakkai Zasshi; 1995 Jun; 86(6):1156-63. PubMed ID: 7609359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
    Buckner JC; Brown LD; Kugler JW; Cascino TL; Krook JE; Mailliard JA; Kardinal CG; Tschetter LK; O'Fallon JR; Scheithauer BW
    J Neurosurg; 1995 Mar; 82(3):430-5. PubMed ID: 7861221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
    Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
    Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.